AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1617519 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior myocardial infarction with reperfusion
Number of subjects: 28
Study 1617519 — intervention group
Group type: COMPARATOR
Intervention: Anterior myocardial infarction without reperfusion
Number of subjects: 28
Study 1617519 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior myocardial infarction with reperfusion
Number of subjects: 28
Study 1617519 — intervention group
Group type: COMPARATOR
Intervention: Inferior myocardial infarction without reperfusion
Number of subjects: 28
Study 6361284 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etretinate
Number of subjects: 0
Study 6361284 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29095358 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral spironolactone treatment
Number of subjects: 41
Study 29095358 — intervention group
Group type: COMPARATOR
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 41
Study 29984418 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided internet cognitive-behavioral treatment (ICBT) for perfectionism
Number of subjects: 67
Study 26242288 — intervention group
Group type: COMPARATOR
Intervention: 0 mg nicotine gum
Number of subjects: 42
Study 26242288 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 42
Study 26242288 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 42
Study 26242288 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg menthol
Number of subjects: 42
Study 26242288 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine + 30 mg menthol
Number of subjects: 42
Study 26242288 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol (in general)
Number of subjects: 42
Study 26242288 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol (in half of participants)
Number of subjects: 42
Study 24918789 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2313
Study 24918789 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2313
Study 24918789 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (both doses)
Number of subjects: 2313
Study 24918789 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin with background sulfonylurea
Number of subjects: 2313
Study 24918789 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin without background sulfonylurea
Number of subjects: 2313
Study 24918789 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 2313
Study 24918789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2313
Study 22840866 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.8 mg
Number of subjects: 40
Study 22840866 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 40
Study 22840866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20399815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bad news consultation (BN)
Number of subjects: 20
Study 20399815 — intervention group
Group type: EXPERIMENTAL
Intervention: History taking consultation (HT)
Number of subjects: 20
Study 20399815 — intervention group
Group type: COMPARATOR
Intervention: Reading aloud
Number of subjects: 20
Study 20399815 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported stress (STAI and VAS)
Number of subjects: 20
Study 17511194 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100
Study 17511194 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 100
Study 16613275 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (CZ) combined with electroacupuncture (EA)
Number of subjects: 90
Study 16613275 — intervention group
Group type: COMPARATOR
Intervention: Clozapine (CZ) alone
Number of subjects: 90
Study 12937858 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral suspension of megestrol acetate (MA) at a daily dose of 480-840 mg
Number of subjects: 22
Study 12937858 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral suspension of megestrol acetate (MA)
Number of subjects: 22
Study 11732527 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 15 microg kg(‐1) min(‐1)
Number of subjects: 100
Study 11732527 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 20 microg kg(‐1) min(‐1)
Number of subjects: 100
Study 11732527 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Intralipid 1 ml h(‐1))
Number of subjects: 100
Study 8894060 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 74
Study 8894060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 1837776 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 664
Study 6136288 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam
Number of subjects: 150
Study 6136288 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) lorazepam
Number of subjects: 150
Study 31484004 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (Glue)
Number of subjects: 189
Study 31484004 — intervention group
Group type: COMPARATOR
Intervention: Control (stapler or manual suture only)
Number of subjects: 189
Study 30401369 — intervention group
Group type: EXPERIMENTAL
Intervention: Opsite combined with wet gauze (normal saline group)
Number of subjects: 41
Study 30401369 — intervention group
Group type: EXPERIMENTAL
Intervention: Opsite combined with wet gauze and eye ointment (ointment group)
Number of subjects: 41
Study 26329135 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cruciferous vegetable intake
Number of subjects: 54
Study 24444360 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical vein injection of 800 mcg misoprostol dissolved in 20 mL of normal saline
Number of subjects: 46
Study 24444360 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving 20 mL of normal saline
Number of subjects: 46
Study 22399327 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 215
Study 22399327 — intervention group
Group type: COMPARATOR
Intervention: In-person counseling
Number of subjects: 215
Study 22399327 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected participants
Number of subjects: 215
Study 22399327 — intervention group
Group type: COMPARATOR
Intervention: Non-affected participants
Number of subjects: 215
Study 22399327 — intervention group
Group type: COMPARATOR
Intervention: Both groups (affected and non-affected)
Number of subjects: 215
Study 22399327 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone pre-counseling
Number of subjects: 215
Study 20231061 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation docetaxel (CD)
Number of subjects: 243
Study 20231061 — intervention group
Group type: COMPARATOR
Intervention: Observation (OB)
Number of subjects: 243
Study 20231061 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 243
Study 17711616 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 4308
Study 17711616 — intervention group
Group type: COMPARATOR
Intervention: Current asthma therapy (control)
Number of subjects: 4308
Study 15966467 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride/Specifar (test preparation)
Number of subjects: 24
Study 12472990 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Number of subjects: 0
Study 12472990 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy
Number of subjects: 0
Study 12472990 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0
Study 12472990 — intervention group
Group type: EXPERIMENTAL
Intervention: Local antibiotic therapy combined with scaling and root planing
Number of subjects: 0
Study 9461137 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with significant hypesthesia (23 patients, 19.8% identified with monofilaments; 29 patients, 25.0% identified with brush strokes)
Number of subjects: 116
Study 9461137 — intervention group
Group type: COMPARATOR
Intervention: Patients without significant hypesthesia
Number of subjects: 116
Study 8589139 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin (IVIG) prophylaxis
Number of subjects: 376
Study 8589139 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole prophylaxis
Number of subjects: 376
Study 8589139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study 2220915 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2.0 gm of elemental calcium as calcium carbonate)
Number of subjects: 189
Study 2220915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 387330 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 18
Study 387330 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 18
Study 31628486 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO (continuing csDMARD therapy)
Number of subjects: 125
Study 31628486 — intervention group
Group type: COMPARATOR
Intervention: MONO (withdrawing csDMARD therapy)
Number of subjects: 125
Study 31628486 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO
Number of subjects: 125
Study 31628486 — intervention group
Group type: COMPARATOR
Intervention: MONO
Number of subjects: 125
Study 30501015 — intervention group
Group type: EXPERIMENTAL
Intervention: Upward contrast social comparisons (SCs)
Number of subjects: 240
Study 30501015 — intervention group
Group type: EXPERIMENTAL
Intervention: Upward identification social comparisons (SCs)
Number of subjects: 240
Study 30501015 — intervention group
Group type: EXPERIMENTAL
Intervention: Downward identification social comparisons (SCs)
Number of subjects: 240
Study 28183505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 2098
Study 28183505 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent
Number of subjects: 2098
Study 28183505 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stent types
Number of subjects: 2098
Study 25892082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 30
Study 25892082 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine
Number of subjects: 30
Study 25892082 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine
Number of subjects: 30
Study 25892082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin and Dihydralazine
Number of subjects: 30
Study 22343209 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus patient activation intervention (n = 43)
Number of subjects: 84
Study 22343209 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 41)
Number of subjects: 84
Study 20410322 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 100
Study 20410322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19474512 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP therapy (rituximab combined with cyclophosphamide, doxorubicin, vincristine, and predonisolone)
Number of subjects: 7
Study 19474512 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=10)
Number of subjects: 7
Study 17265094 — intervention group
Group type: EXPERIMENTAL
Intervention: HES preload group (15 ml x kg(‐1) before spinal anesthesia, n = 18)
Number of subjects: 54
Study 17265094 — intervention group
Group type: EXPERIMENTAL
Intervention: HES coload group (15 ml x kg(‐1) after induction of spinal anesthesia, n = 18)
Number of subjects: 54
Study 17265094 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rapid infusion, n = 18)
Number of subjects: 54
Study 17265094 — intervention group
Group type: EXPERIMENTAL
Intervention: HES preload group
Number of subjects: 54
Study 17265094 — intervention group
Group type: EXPERIMENTAL
Intervention: HES coload group
Number of subjects: 54
Study 17265094 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 54
Study 14966821 — intervention group
Group type: EXPERIMENTAL
Intervention: Respimat SMI 10/25
Number of subjects: 535
Study 14966821 — intervention group
Group type: EXPERIMENTAL
Intervention: Respimat SMI 20/50
Number of subjects: 535
Study 14966821 — intervention group
Group type: COMPARATOR
Intervention: CFC-MDI 40/100
Number of subjects: 535
Study 14966821 — intervention group
Group type: EXPERIMENTAL
Intervention: Respimat SMI
Number of subjects: 535
Study 11739069 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion sustained-release (100 mg-300 mg/day)
Number of subjects: 100
Study 11739069 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (10 mg-40 mg/day)
Number of subjects: 100
Study 11739069 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion and Paroxetine (combined)
Number of subjects: 100
Study 11739069 — intervention group
Group type: COMPARATOR
Intervention: Remitters (compared to Partial Responders and Nonresponders)
Number of subjects: 100
Study 10195027 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Delivered Partner Medication (PDPM)
Number of subjects: 178
Study 10195027 — intervention group
Group type: COMPARATOR
Intervention: Partner Referral Cards (Control)
Number of subjects: 178
Study 7842362 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms aqueous nasal spray twice daily
Number of subjects: 0
Study 7842362 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo spray
Number of subjects: 0
Study 3170392 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dose of netilmicin plus metronidazole
Number of subjects: 40
Study 3170392 — intervention group
Group type: COMPARATOR
Intervention: Thrice daily dose of netilmicin plus metronidazole
Number of subjects: 40
Study 29993976 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved Space Forest
Number of subjects: 0
Study 29993976 — intervention group
Group type: COMPARATOR
Intervention: Original versions of bagging, random forest, and rotation forest
Number of subjects: 0
Study 27964843 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab in addition to trastuzumab and docetaxel
Number of subjects: 808
Study 27964843 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to trastuzumab and docetaxel
Number of subjects: 808
Study 24737406 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (UPPP + Oral Appliance)
Number of subjects: 40
Study 24737406 — intervention group
Group type: COMPARATOR
Intervention: Pure surgery group (UPPP)
Number of subjects: 40
Study 23161360 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml ropivacaine 0.75% plus 20 µg dexmedetomidine (RpD)
Number of subjects: 36
Study 23161360 — intervention group
Group type: COMPARATOR
Intervention: 3 ml ropivacaine 0.75% (R)
Number of subjects: 36
Study 23161360 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml ropivacaine 0.75% plus systemic 20 µg dexmedetomidine (RsD)
Number of subjects: 36
Study 21574873 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of l-arginine (0.075 g·kg(‐1) of body mass)
Number of subjects: 14
Study 21574873 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of l-arginine (0.15 g·kg(‐1) of body mass)
Number of subjects: 14
Study 21574873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 21574873 — intervention group
Group type: EXPERIMENTAL
Intervention: Low and High dose of l-arginine
Number of subjects: 14
Study 19771282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pickle juice
Number of subjects: 9
Study 19771282 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-e drink
Number of subjects: 9
Study 19771282 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 9
Study 17027233 — intervention group
Group type: EXPERIMENTAL
Intervention: Konjac glucomannan (KGM) 1.5 g/meal, 4.5 g/d for 21 days
Number of subjects: 8
Study 15617456 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg once daily
Number of subjects: 147
Study 15617456 — intervention group
Group type: COMPARATOR
Intervention: enalapril 10 mg once daily
Number of subjects: 147
Study 11532240 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI intervention group
Number of subjects: 118
Study 11532240 — intervention group
Group type: COMPARATOR
Intervention: No-MRI intervention group
Number of subjects: 118
Study 9406013 — intervention group
Group type: COMPARATOR
Intervention: MRX-115 (lipid-encapsulated perfluoropropane gas microbubbles)
Number of subjects: 48
Study 8328575 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam plus behavioral therapy
Number of subjects: 15
Study 8328575 — intervention group
Group type: COMPARATOR
Intervention: Triazolam plus sleep-related information
Number of subjects: 15
Study 3016071 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin (1 CU/kg/h, 0-120 min)
Number of subjects: 10
Study 3016071 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin (1 CU/kg/h, 0-120 min) + Cholecystokinin (CCK) (1 IU/kg/h, 60-120 min)
Number of subjects: 10
Study 3016071 — intervention group
Group type: COMPARATOR
Intervention: Control (NaCl infusion study)
Number of subjects: 10
Study 29313359 — intervention group
Group type: COMPARATOR
Intervention: Attention control (physical activity recommendations)
Number of subjects: 175
Study 29313359 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume MICT (45 minutes of moderate-intensity continuous training, 2 days/week)
Number of subjects: 175
Study 29313359 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume HIIT (2 days/week)
Number of subjects: 175
Study 29313359 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume HIIT (20 minutes, 2 days/week)
Number of subjects: 175
Study 29313359 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 175
Study 29313359 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume MICT
Number of subjects: 175
Study 29313359 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume HIIT
Number of subjects: 175
Study 29313359 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume HIIT
Number of subjects: 175
Study 29313359 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management
Number of subjects: 175
Study 27616034 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergoferon
Number of subjects: 156
Study 27616034 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 156
Study 24048736 — intervention group
Group type: COMPARATOR
Intervention: Clinical parameters alone
Number of subjects: 550
Study 24048736 — intervention group
Group type: COMPARATOR
Intervention: Urine peptide biomarkers (FGA1826, FGA1883, FGA2659)
Number of subjects: 550
Study 24048736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensemble model combining clinical parameters with urine biomarkers
Number of subjects: 550
Study 22527984 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-6/omega-3 fatty acid ratio >15
Number of subjects: 80
Study 22527984 — intervention group
Group type: COMPARATOR
Intervention: Folate <5 ug/L
Number of subjects: 80
Study 22527984 — intervention group
Group type: COMPARATOR
Intervention: 25‐hydroxy vitamin D <20 ng/mL
Number of subjects: 80
Study 21275160 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine and general stroke-treatment (135 patients)
Number of subjects: 377
Study 21275160 — intervention group
Group type: COMPARATOR
Intervention: General stroke-treatment only (126 patients)
Number of subjects: 377
Study 18848094 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 47710
Study 18848094 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 47710
Study 18848094 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepine/narcotics
Number of subjects: 47710
Study 18848094 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (administered by OMS)
Number of subjects: 47710
Study 18848094 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (administered by non-OMS)
Number of subjects: 47710
Study 16096449 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel, three times a day during the entire ICU stay
Number of subjects: 228
Study 16096449 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel, three times a day during the entire ICU stay
Number of subjects: 228
Study 16096449 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel
Number of subjects: 228
Study 12045487 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir DF 300 mg once-daily
Number of subjects: 184
Study 12045487 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir DF 300 mg therapy
Number of subjects: 184
Study 12045487 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Number of subjects: 184
Study 12045487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 11053318 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 12
Study 11053318 — intervention group
Group type: COMPARATOR
Intervention: Placebo (citrate)
Number of subjects: 12
Study 9356491 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir (IDV)/Zidovudine (ZDV)/Lamivudine (3TC)
Number of subjects: 10
Study 9356491 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV)/Lamivudine (3TC)
Number of subjects: 10
Study 9356491 — intervention group
Group type: COMPARATOR
Intervention: Indinavir (IDV)
Number of subjects: 10
Study 1326582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal interferon‐alpha 2b, ipratropium, and oral naproxen; treatment started 24 hours after inoculation, continued three times a day for 4 days
Number of subjects: 24
Study 1326582 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 3887553 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg twice daily)
Number of subjects: 79
Study 3887553 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 79
Study 3887553 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 79
Study 31725463 — intervention group
Group type: EXPERIMENTAL
Intervention: Formative assessment condition
Number of subjects: 0
Study 31725463 — intervention group
Group type: COMPARATOR
Intervention: Summative assessment condition
Number of subjects: 0